Spreadsheet: 63caf7b7-67e7-457c-9fb8-23757ced4d60
Sheet: Tb45

 | Estimated Vaccination Coverage^ with Individual Vaccines and Vaccination Series Among Children 19-35 Months of Age by Race/Ethnicity* -- US, National Immunization Survey, Q3/2010-Q2/2011†
[NAME] | US National | White only,                        non-Hispanic | Black only,                         non-Hispanic | Hispanic | American Indian or [NAME] only, non-Hispanic | Asian only, non-Hispanic | Native Hawaiian or other Pacific Islander only, non-Hispanic | Multiple Race, non-Hispanic
3+DTaP¥ | 95.2±0.6 | 95.4±0.7 | 94.8±1.9 | 95.1±1.4 | 95.5±3.5 | 98.1±1.2 | 98.7±2.6 | 93.0±3.2
4+DTaP‡ | 84.3±1.0 | 84.8±1.3 | 82.4±3.1 | 83.3±2.5 | 79.8±7.9 | 91.1±2.7 | 91.1±7.1 | 86.0±4.4
3+Polio§ | 93.7±0.7 | 93.7±0.8 | 93.4±2.1 | 93.7±1.6 | 94.5±3.9 | 96.0±2.1 | 98.7±2.6 | 92.3±3.2
1+MMRll | 91.7±0.8 | 91.0±0.9 | 90.7±3.1 | 93.2±1.4 | 92.1±6.2 | 94.2±2.2 | 96.9±3.8 | 91.3±3.3
3+Hib¶ | 93.1±0.7 | 93.6±0.8 | 91.2±2.5 | 93.4±1.5 | 92.4±5.1 | 93.3±2.5 | 98.0±2.8 | 92.0±3.3
Hib-PS** | 93.4±0.7 | 93.8±0.8 | 91.3±2.5 | 93.5±1.5 | 95.3±3.5 | 94.0±2.4 | 98.0±2.8 | 92.4±3.3
Hib-FS†† | 76.2±1.2 | 77.0±1.4 | 72.3±3.3 | 74.8±2.7 | 80.2±7.9 | 80.8±5.5 | 90.6±6.3 | 81.0±4.4
3+HepB‡‡ | 90.8±0.8 | 90.6±1.0 | 91.7±2.2 | 90.5±1.9 | 96.8±2.9 | 93.8±2.9 | 95.0±5.5 | 89.8±3.4
[NAME] dose§§ | 66.6±1.3 | 66.0±1.6 | 70.1±3.7 | 65.6±3.2 | 78.4±8.0 | 67.3±6.6 | 86.2±9.3 | 65.6±5.7
1+Varllll | 90.7±0.8 | 89.7±1.0 | 89.7±3.2 | 92.0±1.7 | 91.5±6.0 | 94.5±2.1 | 95.2±5.7 | 91.5±3.1
3+PCV¶¶ | 93.2±0.7 | 93.3±0.8 | 92.5±2.3 | 93.4±1.7 | 93.6±3.9 | 94.1±2.1 | 97.8±3.1 | 91.9±3.4
4+PCV*** | 84.4±1.0 | 85.1±1.2 | 81.5±3.5 | 83.9±2.4 | 82.1±7.4 | 87.1±3.4 | 94.0±5.3 | 85.7±3.9
2+HepA††† | 50.7±1.4 | 48.0±1.7 | 50.6±3.8 | 54.8±3.3 | 53.5±9.6 | 54.4±7.7 | NA | 50.2±6.0
Rotavirus‡‡‡ | 64.3±1.3 | 64.9±1.7 | 59.0±3.7 | 65.6±3.2 | 53.6±9.7 | 67.9±6.4 | NA | 65.6±5.5
4:3:1§§§ | 82.3±1.1 | 81.9±1.3 | 81.3±3.1 | 81.9±2.5 | 79.8±7.9 | 88.9±3.3 | 89.8±7.6 | 85.0±4.5
4:3:1:3llllll | 81.1±1.1 | 80.8±1.3 | 79.6±3.2 | 81.1±2.6 | 79.8±7.9 | 85.8±3.8 | 89.1±7.7 | 84.3±4.5
4:3:1:3-PS¶¶¶ | 81.2±1.1 | 81.0±1.3 | 79.6±3.2 | 81.2±2.6 | 79.8±7.9 | 86.4±3.7 | 89.1±7.7 | 84.6±4.5
4:3:1:4-FS**** | 71.1±1.3 | 71.3±1.5 | 67.7±3.5 | 70.2±2.9 | 77.1±8.0 | 76.6±5.9 | 87.2±8.2 | 76.2±5.0
4:3:1:3:3:1€ | 76.5±1.2 | 76.0±1.4 | 74.8±3.7 | 76.8±2.7 | 76.7±8.2 | 81.5±4.6 | 86.4±9.0 | 79.2±4.8
4:3:1:0:3:1ς | 77.5±1.2 | 77.1±1.4 | 76.0±3.7 | 77.5±2.7 | 76.7±8.2 | 84.1±4.3 | 87.1±8.8 | 79.8±4.7
4:3:1:3:3:1-PS€€ | 76.6±1.2 | 76.2±1.4 | 74.8±3.7 | 76.9±2.7 | 76.7±8.2 | 82.2±4.5 | 86.4±9.0 | 79.5±4.7
4:3:1:4:3:1-FSςς | 67.1±1.3 | 67.1±1.6 | 63.6±3.8 | 66.5±3.0 | 74.1±8.3 | 72.9±6.3 | 84.5±9.4 | 71.6±5.2
4:3:1:3:3:1:4€€€ | 72.4±1.2 | 72.3±1.5 | 69.7±3.8 | 72.6±2.9 | 71.9±8.7 | 76.9±5.1 | 84.4±9.6 | 75.4±4.9
4:3:1:0:3:1:4ςςς | 73.1±1.2 | 73.0±1.5 | 70.7±3.8 | 73.2±2.9 | 71.9±8.7 | 77.6±5.1 | 84.8±9.5 | 75.7±4.9
4:3:1:3:3:1:4-PS€€€€ | 72.5±1.2 | 72.4±1.5 | 69.7±3.8 | 72.8±2.9 | 71.9±8.7 | 77.5±5.1 | 84.4±9.6 | 75.7±4.9
4:3:1:4:3:1:4-FSςςςς | 64.5±1.3 | 64.4±1.6 | 60.8±3.8 | 64.4±3.1 | 69.5±8.8 | 69.1±6.6 | NA | 69.5±5.3
 | ^ Estimate=NA (Not Available) if the unweighted sample size for the denominator was <30 or (CI half width)/Estimate > 0.588 or (CI half width) >10. Estimates presented as point estimate (%) ± 95% Confidence Interval.
 | * Self-reported by respondent. Children of Hispanic ethnicity may be of any race.
 | † Children in the Q3/2010-Q2/2011 National Immunization Survey were born from July 2007 through November 2009.
 | ¥  3 or more doses of any diphtheria and tetanus toxoids and pertussis vaccines including diphtheria and tetanus toxoids, and any acellular pertussis vaccine (DTaP/DTP/DT).
 | ‡ 4 or more doses of DTaP.
 | § 3 or more doses of any poliovirus vaccine.
 | ll 1 or more doses of measles-mumps-rubella vaccine.
 | ¶ 3 or more doses of Haemophilus influenzae type b (Hib) vaccine.
 | ** Primary series Hib: ≥2 or ≥3 doses of Haemophilus influenzae type b (Hib), depending on brand type.
 | †† Full series Hib:  ≥3 or ≥4 doses of Hib vaccine depending on product type received (includes primary series plus the booster dose).
 | ‡‡ 3 or more doses of hepatitis B vaccine.
 | §§ 1 or more doses of hepatitis B vaccine administered between birth and age 3 days.
 | llll 1 or more doses of varicella at or after child's first birthday, unadjusted for history of varicella illness.
 | ¶¶ 3 or more doses of pneumococcal conjugate vaccine (PCV).
 | *** 4 or more doses of PCV.
 | ††† 2 or more doses of Hepatitis A vaccine.
 | ‡‡‡ ≥2 or ≥3 doses of [NAME] vaccine, depending on product type received (≥2 doses for Rotarix® [RVI] or ≥3 doses for RotaTeq® [RV5]).
 | §§§ 4 or more doses of DTaP, 3 or more doses of poliovirus vaccine, and 1 or more doses of any MMR vaccine.
 | llllll 4:3:1 plus 3 or more doses of Hib vaccine of any type.
 | ¶¶¶ 4:3:1 plus the primary series Hib.
 | ****  4:3:1 plus the full series Hib.
 | € 4:3:1 plus 3 or more doses of Hib vaccine of any type, 3 or more doses of HepB vaccine, and 1 or more doses of varicella vaccine.
 | ς 4:3:1 plus 3 or more doses of HepB vaccine and 1 or more doses of varicella vaccine. Hib vaccine is excluded.
 | €€ 4:3:1 plus primary series of Hib vaccine, 3 or more doses of HepB vaccine, and 1 or more doses of varicella vaccine.
 | ςς 4:3:1 plus full series of Hib vaccine, 3 or more doses of HepB vaccine, and 1 or more doses of varicella vaccine.
 | €€€ 4:3:1 plus ≥3 doses of Hib vaccine of any type, 3 or more doses of HepB, 1 or more doses of varicella vaccine, and 4 or more doses of PCV.
 | ςςς  4:3:1 plus 3 or more doses of HepB vaccine, 1 or more doses of varicella vaccine, and 4 or more doses of PCV.  Hib vaccine is excluded.
 | €€€€ 4:3:1 plus primary series Hib vaccine, 3 or more doses of HepB, 1 or more doses of varicella vaccine, and 4 or more doses of PCV.
 | ςςςς 4:3:1 plus full series Hib vaccine, 3 or more doses of HepB, 1 or more doses of varicella vaccine, and 4 or more doses of PCV.